Survival outcomes of sentinel lymph node biopsy alone versus back-up systematic lymph node dissection in high-risk endometrial Cancer: A Turkish Gynecologic Oncology group study (TRSGO-SLN-007)

Gokce A., TAŞKIN S., Vatansever D., YALÇIN İ., Altin D., TAKMAZ Ö., ...More

European Journal of Obstetrics and Gynecology and Reproductive Biology, vol.308, pp.78-84, 2025 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 308
  • Publication Date: 2025
  • Doi Number: 10.1016/j.ejogrb.2025.02.050
  • Journal Name: European Journal of Obstetrics and Gynecology and Reproductive Biology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database
  • Page Numbers: pp.78-84
  • Keywords: Endometrial cancer, High-risk endometrial cancer, Sentinel, Survival
  • Ankara University Affiliated: Yes

Abstract

Background and Objectives: Investigate whether there is an oncological benefit of performing back up systematic lymphadenectomy in addition to bilateral sentinel node biopsy. Methods: This multicentre retrospective study included patients with high-risk endometrial cancer treated at four gynaecological oncology clinics in Turkey between 2014 and 2023. Patients were stratified according to both conventional and ESGO risk criteria, and within each category were divided into two groups respectively “Sentinel Lymph Node Biopsy Group (SLN-only)” and “Back-up Lymphadenectomy Group (Back-up LND)”. Disease-free survival (DFS) and overall survival (OS) were compared using univariate and multivariable Cox regression analyses. Results: 56 patients in the SLN-only group and 158 patients in the Back-up LND group comprised of the Conventional High-Risk Group (CONV-HR) in the analysis. There was no significant difference statistically in terms of DFS (Log-Rank P = 0.29) and OS (Log-Rank P = 0.99). The European Society of Gynaecologic Oncology (ESGO) High-Risk Group (ESGO-HR) consisted of 44 patients in the SLN-only group and 133 patients in the Back-up LND group were included. The median follow-up periods were 27 months (IQR = 15–38) and 28 (IQR = 16–38) months, respectively. Recurrence rate was 14.1 % and mortality rate was 9.6 %. There was no significant difference statistically in terms of DFS (Log-Rank P = 0.342) and OS (Log Rank P = 0.488). Conclusion: Sentinel lymph node biopsy is a safe and effective method for lymph node assessment in high-risk and clinical early-stage endometrial cancer. The addition of systematic lymphadenectomy did not provide any oncological benefit in terms of survival outcomes.